
Guillaume Bonnet
@guilbon
Interventional cardiologist @CHUBordeaux. MD, PhD. Research Fellow @crfheart
ID: 1563961200
02-07-2013 19:55:23
5,5K Tweet
3,3K Followers
2,2K Following



💡We are delighted to share the initial experience of orthotopic TTVR in 🇪🇸 #TreatTR 📌Published in CCIjournal 🔗 shorturl.at/1XTYj Teamwork led by Rodrigo Estévez and Manuel Barreiro-Perez from Alvaro Cunqueiro Hospital Cardiología Vigo





Are you part of a Heart Team or a Startup? Don’t miss your chance to save up to 40% on registration for #NYValves2025! ⏰ Deadline Approaching: June 12 at 11:59 PM EDT! 🫀 Heart Teams: nyvalvesconference.com/heart-team-dis… 🚀 Startups: nyvalvesconference.com/startup-discou… #CardioX #CardioTwitter







It’s officially go time! 🚀 #NYValves2025 kicks off with our Opening Session — the start of 3 powerful days filled with expert insights, live education, & the future of structural heart care. 🫀💡 Juan F. Granada Marty Leon Philippe Genereux Mayra Guerrero, MD Mariell Jessup Vanderbilt Structural Heart & Valve Center



What a kickoff to #NYValves2025! 🚀 From cutting-edge science to hands-on sessions, today was packed with innovation, education, and amazing connections. Here’s a glimpse of the excitement from Day 1! 🔥🫀 #CardioX #CardioTwitter #CardioEd #CardioResearch Juan F. Granada


Part 3️⃣: thomas modine, Lionnel Leroux, Julien Ternacle & Guillaume Bonnet, Atlantic Valve Academy, complete LuX-Valve #TTVR in an 81yo male with COPD, paroxysmal AF & severe TR. After confirming seal, the valve is released. The system is de-flexed & retracted into the RA.


Cardiovascular Research Foundation #NYValves2025 #LBCT 2-yr Outcomes Following Transfemoral Transseptal Transcatheter Mitral Valve Replacement: Intrepid TMVR Early Feasibility Study Dr. Gilbert Tang 🔹No device-related deaths, disabling strokes, or reinterventions 🔹Improvements in stroke volume, CO, RV


Cardiovascular Research Foundation #NYValves2025 Clinical & QOL Outcomes w PASCAL System in Early Experience From STS/ ACC TVT Registry Minneapolis Heart Institute Foundation Nimesh Desai 🔹STS registry valuable for post-marketing surveillance 🔹25% not in echo analysis & 40% not in QOL analysis 🔹Did any subgroups have
